Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...
Dizal Pharmaceutical
National Reimbursement Drug List (NRDL) Negotiations Conclude with Lower Generic Drug Approval Rate
The National Reimbursement Drug List (NRDL) negotiations for the year have concluded, with less than...
Dizal Pharmaceutical’s Q3 2024 Revenues Soar 236% YOY on Strong Product Sales
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has released its financial report for the third...
Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has announced that...
Dizal Pharmaceutical’s Surufatinib Earns CDE Consideration for Breakthrough Therapy in EGFR exon20ins NSCLC
Dizal Pharmaceutical, a biopharmaceutical company based in China, has announced that the Center for Drug...
Dizal Pharmaceutical’s Sunvozertinib Shows Promising Results in WU-KONG Series Study at ESMO 2024
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has presented updates...
Dizal Pharmaceutical’s Financial Turnaround Continues with 33% Net Loss Reduction in H1 2024
Dizal Pharmaceutical Co., Ltd, a pharmaceutical entity listed in Shanghai (SHA: 688192), has unveiled its...
Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...
Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...
Dizal Pharmaceutical’s Sunvozertinib Logs RMB 91.29 Million in Sales Following EGFR Inhibitor Approval
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China, has announced that its...
Dizal Pharmaceutical Presents Positive Trial Data for Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd, (SHA: 688192), a spin-off from AstraZeneca (AZ, NASDAQ: AZN) China...
Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments
China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...
Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...
Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that the National Medical Products Administration...
Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been...
Dizal Pharmaceutical’s Sunvozertinib Approved by China’s NMPA for NSCLC Treatment
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that it has received market approval...
Dizal Pharmaceutical’s Sunvozertinib Gets EU Approval for Global Phase III Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving the green light from EU...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
Dizal Pharmaceutical Presents Updates on Sunvozertinib and Golidocitinib at ASCO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...